These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 30267839)

  • 1. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
    Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
    Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
    Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
    Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.
    Dhami J; Hirshfield KM; Ganesan S; Hellmann M; Rojas V; Amorosa JK; Riedlinger GM; Zhong H; Ali SM; Pavlick D; Elvin JA; Rodriguez-Rodriguez L
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29588307
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
    Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
    Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
    Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of targetable FGFR gene fusions in diverse cancers.
    Wu YM; Su F; Kalyana-Sundaram S; Khazanov N; Ateeq B; Cao X; Lonigro RJ; Vats P; Wang R; Lin SF; Cheng AJ; Kunju LP; Siddiqui J; Tomlins SA; Wyngaard P; Sadis S; Roychowdhury S; Hussain MH; Feng FY; Zalupski MM; Talpaz M; Pienta KJ; Rhodes DR; Robinson DR; Chinnaiyan AM
    Cancer Discov; 2013 Jun; 3(6):636-47. PubMed ID: 23558953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Mack PC; Keller-Evans RB; Li G; Lofgren KT; Schrock AB; Trabucco SE; Allen JM; Tolba K; Oxnard GR; Huang RSP
    Oncologist; 2024 Aug; 29(8):e984-e996. PubMed ID: 38401173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
    Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
    ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.